We help injury victims recover for accidents and injuries caused by consumer products, including metal hip implants, prescription drugs, and dangerous medical devices. Find out which devices have been known to cause serious side effects, and how we can help you get compensation.

Brought to market by Novo Nordisk, Ozempic is an injectable version of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide. Its primary approval targeted adults suffering from Type 2 diabetes. However, its popularity skyrocketed, particularly for off-label weight loss usage, a trend further amplified by celebrity endorsements.

Impressively, around 45% of adults showed interest in using a reputedly safe prescription drug like Ozempic for weight loss. This surge in demand propelled the drug's revenue from $2.1 billion to an astounding $3.2 billion within a year.

But as its stature grew, so did concerns. Beyond the usual application for diabetes management, many were drawn to the allure of its weight management properties. Yet, despite the glowing testimonials and revenue figures, troubling reports began to surface.

At the heart of the issue is a case from Louisiana. A woman has taken Novo Nordisk to court, alleging the firm's negligence in adequately informing users about potential severe side effects tied to Ozempic. The list is alarmingly extensive: Gastroparesis, Gallbladder Disease, Pancreatic Cancer, and injuries to the stomach and intestines.

As Ozempic's popularity surged, so did alarming revelations about its potential repercussions. The drug, while heralded for its benefits, has been linked to a series of severe health concerns, including pancreatitis, gallbladder complications, bowel obstructions, and sudden kidney issues. Between 2018 and the early part of 2023, a concerning number of over 13,000 adverse incidents related to Ozempic were reported to the FDA, a testament to the gravity of these side effects.

In 2022, the FDA uncovered potential links between Ozempic and acute cholecystitis. An alarming 42% of patients diagnosed with gallbladder issues began showing symptoms within the initial three months of using Ozempic. Despite these revelations, Novo Nordisk's response was disturbingly delayed.

At McGartland, we champion your rights. Our dedicated team of attorneys, paralegals, and case managers stand ready to assist, requiring no upfront fees.  McGartland Law Firm has been representing injury clients for over 25 years, and work with attorneys in every state to give all injured patients the benefit of our experience.  We're a call away, ready to furnish essential information about your case's eligibility. Call 1-866-832-9300 for a free consultation.